AstraZeneca and Oxford University announce landmark agreement for global development and distribution of the University’s COVID-19 vaccine

The collaboration aims to bring to patients the potential recombinant adenovirus vaccine known as ChAdOx1 nCoV-19, which entered Phase I clinical trials last week to study safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in Southern England


AstraZeneca Plc.